Sugawara I, Yamada H, Nakamura H, Sumizawa T, Akiyama S, Masunaga A, Itoyama S
Department of Pathology, Saitama Medical Center, Saitama Medical School, Japan.
Int J Cancer. 1995 Oct 20;64(5):322-5. doi: 10.1002/ijc.2910640507.
The expression of multidrug-resistance-associated protein (MRP) was assessed in various types of untreated lung cancer using an immunohistochemical technique. MRP was abundantly expressed in 28 of 59 adenocarcinoma specimens (47%) and its expression was associated with the degree of glandular differentiation of the tumor. MRP expression in well-differentiated adenocarcinomas (56%) was higher than in poorly differentiated adenocarcinomas (22%) (p < 0.01). lower--20% in squamous-cell carcinomas, 20% in large-cell carcinomas and 0% in small-cell carcinomas and carcinoids. RT-PCR showed that the MRP-positive adenocarcinomas and squamous-cell carcinomas expressed mrp mRNA significantly. Immunoelectron microscopically, MRP was localized in the plasma membrane and rough endoplasmic reticulum. It is thus important to take MRP into account when considering chemotherapy for lung cancers because levels of mdr I gene product, another multidrug-resistance gene family, are low in untreated lung cancers.
采用免疫组化技术评估未治疗的各类肺癌中多药耐药相关蛋白（MRP）的表达情况。59例腺癌标本中有28例（47%）MRP呈高表达，其表达与肿瘤的腺管分化程度相关。高分化腺癌中MRP的表达率（56%）高于低分化腺癌（22%）（p<0.01）。鳞状细胞癌中的表达率较低——为20%，大细胞癌为20%，小细胞癌和类癌为0%。逆转录聚合酶链反应（RT-PCR）显示，MRP阳性的腺癌和鳞状细胞癌显著表达mrp mRNA。免疫电镜检查显示，MRP定位于质膜和粗面内质网。因此，在考虑肺癌化疗时，考虑MRP很重要，因为另一个多药耐药基因家族mdr I基因产物在未治疗的肺癌中的水平较低。
